1. Cappellini M. D. et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American J Hematol. 2017; 92(10): 1068–1078.
2. Melenovsky V. et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. European J of Heart Fail. 2017; 19(4): 522–530.
3. Roemhild K. et al. Iron metabolism: pathophysiology and pharmacology. Trends in Pharmacological Sciences. 2021; 42: 640–656.
4. Anand I. S., Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018; 138(1): 80–98.
5. Babitt J. L. Ironing out pulmonary arterial hypertension. PNAS. 2019; 116 (26): 12604-12606.
6. Anker S. D. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018; 20: 125–133.
7. Martens P. et al., the PVDOMICS Study Group. Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications. European Heart Journal. 2023; 44(22): 1979–1991.
8. Rifai N. (ed.). Tietz textbook of laboratory medicine, Seventh edition. Elsevier, St. Louis, Missouri, 2022.
9. Soon E. et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension Thorax. 2011 Apr; 66(4): 326-332.
10. Vinke P. et al. Prevalence of Micronutrient Deficiencies and Relationship with Clinical and Patient-Related Outcomes in Pulmonary Hypertension Types I and IV. Nutrients. 2021; 13: 3923.
11. Жиленкова Ю. И., Симакова М. А. и др. Исследование обмена железа у пациентов с легочной артериальной гипертензией и хронической тромбоэмболической легочной гипертензией. Тезисы XI Всероссийского конгресса «Легочная гипертензия–2023», 14–15.12.2023. Системные гипертензии. 2023; 20(4): 41.
12. Авдеев С. Н. и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации, 2020. Российский кардиологический журнал. 2021; 26(12): 4683.
13. Чазова И. Е. и др. Евразийские рекомендации по диагностике и лечению легочной гипертензии (2023). Евразийский Кардиологический Журнал. 2024; (1): 6-85.
14. Aversa M., Porter S., Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf. 2015; 38: 419–435.
15. Wei A. et al. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. J Am Heart Assoc. 2016; 5: e003896.
16. Zhang Y-J. et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2019; 9(3): 239–249.
17. Simonneau G. et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014; 172(2): 332–339.
18. McLaughlin V. et. al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015; 46(2): 405–413.
19. Jansa P., Pulido T. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. Am J Cardiovasc Drugs. 2018; 18: 1–11.
20. Galiè N. et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9): 834–844.
21. Grünig E. et al. Randomized trial of macitentan/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024; 83: 473–484.
22. Железодефицитная анемия. Клинические рекомендации Минздрава РФ, 2021 г. https://npngo.ru/biblioteka/klinicheskie_rekomendatsii__2021_god_
23. Olsson K. M. et al. Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. Eur Respir J. 2020; 56(5): 2000616.
24. Howard L. S. G. E. et al. Supplementation with iron in pulmonary arterial hypertension. two randomized crossover trials. Ann Am Thorac Soc. 2021; 18(6): 981–988.
25. Humbert M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43: 3618–3731.
26. Kramer T. et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study. Journal of Cachexia, Sarcopenia and Muscle. 2021; 12(5): 1501–1512.